



ChemComm

Polymyxin Derivatives as Broad-Spectrum Antibiotic Agents

Journal:	<i>ChemComm</i>
Manuscript ID	CC-COM-09-2019-006908.R1
Article Type:	Communication

SCHOLARONE™
Manuscripts

COMMUNICATION

Polymyxin Derivatives as Broad-Spectrum Antibiotic Agents

Ma Su,^a Minghui Wang,^a Yuzhu Hong,^b Alekhya Nimmagadda,^a Ning Shen,^b Yan Shi,^a Ruixuan Gao,^a En Zhang,^{a,c} Chuanhai Cao,^{b,*} and Jianfeng Cai^{a,*}

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

We designed a few polymyxin derivatives which have broad-spectrum antimicrobial activity. Lead compound P1 could disrupt bacterial membranes rapidly without developing resistance, inhibit biofilms formed by *E. coli*, and exhibit excellent *in vivo* activity in the MRSA-infected thigh burden mouse model.

Polymyxins were secondary metabolite nonribosomal peptides produced by a Gram-positive bacterium *Paenibacillus polymyxa* and first recognized as antibiotic agents in the 1940s.¹ Among five polymyxins (polymyxins A to E), two of them have been used in clinic: polymyxin B and E (also known as colistin).² Both polymyxin B and colistin exhibit antibacterial activities against a narrow spectrum of Gram-negative pathogens such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae*.³

Colistin is a complex, multicomponent antibiotic mixture.⁴ Two major constituents are colistin A and colistin B, with identical head groups but fatty acyl tails of different lengths: colistin A contains a 6-methyloctanoic acid residue, whereas colistin B bears a 6-methylheptanoic acyl tail (Figure 1).⁵ In the clinical setting, colistin is administered in the form of colistin methanesulfonate (CMS), a less toxic and nonactive prodrug.⁶ However, the early clinical experience before the 1970s, the parenteral administration of PMB and colistin (or its nonactive prodrug colistin methanesulfonate), led to concern over the potential nephrotoxicity and neurotoxicity, and their clinical use waned for a long period.⁷⁻⁹

The mechanism of colistin has been extensively investigated and proposed. The outer membrane of Gram-negative bacteria constitutes a permeable barrier.¹⁰ Polymyxin can directly interact with the lipid A component of the lipopolysaccharide (LPS) of the outer membrane.¹¹ The current understanding of




Figure 1. (a) Structure of colistin (polymyxin E); (b) The numbering of positions in colistin.

structure-activity relationship (SAR) is that amphipathic nature of polymyxin is crucial¹²: cationic residues and hydrophobic groups. There are several key domains crucial for interaction with lipid A: Dab side chain with positive charge, the heptapeptide backbone, hydrophobic fatty acyl tail at N-terminal and hydrophobic motif at position 6 and 7. (Figure 1) Indeed, polymyxins have weak antimicrobial activity toward Gram-positive bacteria due to the lack of LPS in their membranes.

The WHO has identified antibiotic resistance as one of the three greatest threats to human health.¹³ The world is now facing an enormous threat from the emergence of bacteria that are resistant to almost all available antibiotics.¹⁴ In recent years, virtually no novel drugs targeting multidrug-resistant (MDR) Gram-negative bacteria (especially *P. aeruginosa*, and *K. pneumoniae*) have been developed.¹² The polymyxins are

^a Department of Chemistry, University of South Florida, Tampa, FL 33620.

^b College of Pharmacy, University of South Florida, Tampa, FL 33620.

^c School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

increasingly being used as last-line therapy to treat otherwise untreatable serious infections caused by Gram-negative bacteria that are resistant to essentially all other currently available antibiotics.^{2, 15-17} However, emergence of polymyxin resistance in Gram-negative bacteria has been reported.¹⁸⁻¹⁹ The most common way that Gram-negative bacteria survives from polymyxin by remodeling LPS.²⁰

Our previous studies have suggested that γ -AApeptides may be an alternative class of peptidomimetics combating antibiotic resistance (Figure 2),²¹⁻²² and the lipidation could further enhance antibacterial activity.²³⁻²⁵ Herein, we report the design and investigation of a few polymyxin derivatives modified with γ -AApeptide building blocks and lipid tails. Intriguingly, we show certain polymyxin derivatives exhibit broader spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria.

As shown in Table 1, we designed a few sequences with modifications on collision structural domains. First, the length of fatty acyl group was changed from branched 8 carbons to linear 16 carbons for all the colistin derivatives. We speculated longer tail could help colistin to penetrate bacterial membranes. Additionally, in compound **P2**, L-Dab residues on position 8 and 9 were replaced with a positively charged γ -AA building block, which contains two positive charged groups and presumably mimics L-Dab residues (Table 1). Whereas in **P3**, L-Dab and L-Thr residues on position 1 and 2 were substituted with another γ -AApeptide building block, which contains one positive charged and polar group. At last, we designed compound **P4**, with a change from D-Leu and L-Leu residues to a hydrophobic γ -AApeptide building block bearing two hydrophobic groups. We speculated that inclusion of hydrophobic groups, cationic groups and longer tails would enhance the interaction between these compounds with bacterial membranes, and thereby increase their antibacterial activity.

The antimicrobial activity of these compounds was tested by MIC using 4 different bacterial strains including both multi-drug resistant Gram-positive and Gram-negative bacteria, and results shown in Table 2. Interestingly, **P1**, **P2**, **P3** and **P4** possess good activity against Gram-positive bacterial MRSA with MIC 6.25~25 $\mu\text{g}/\text{mL}$, and as expected, colistin is not active against MRSA, suggesting changing lipid tail could enhance broad-spectrum activity. It is known that colistin is only active against Gram-negative bacterial strains and does not have activity against Gram-positive bacteria strains. Interestingly, all four cyclic peptides are active against both MRSA and *E. coli*, suggesting increasing the length of lipid tail was sufficiently to enhance the broad-spectrum activity of colistin. We believed




Figure 2. The structure of α -peptide and γ -AApeptide

Table 1. Structures of polymyxin mimic cyclic peptides.

Compound	Modified Position	AApeptide building block	Fatty acyl group
P1	None	None	C ₁₆ H ₃₁ O
P2	8,9		C ₁₆ H ₃₁ O
P3	1,2		C ₁₆ H ₃₁ O
P4	6,7		C ₁₆ H ₃₁ O

longer tails could penetrate both Gram-positive and Gram-negative bacterial membranes, and such findings could be used to guide the future design of antibiotic agents. Intriguingly, compound **P1**, which just has a longer lipid tail compared to colistin, has shown the best activity among 4 compounds, indicating inclusion of γ -AApeptide building blocks did not improve the antibacterial activity. We reasoned due to complexity of LPS, change of residues on the cyclic backbone may altered the conformation of the ring structure, leading to weaker interaction with bacterial cell membranes. Moreover, **P1** also exhibited good selectivity, as it has a hemolytic activity of 125 $\mu\text{g}/\text{mL}$, which is 20-fold of its activity toward MRSA. Since compound **P1** exhibited the most potent and broad-spectrum activity, it was investigated further for its ability to disrupt bacteria membranes of MRSA and *E. coli*. Two dyes, 4',6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) (Figure 3), were used to differentiate among cells with either an intact or a damaged membrane. DAPI can permeate the membrane of intact cells therefore shows blue fluorescence regardless of cell viability. In contrast, PI is a DNA intercalator but lacks cell permeability. It fluoresces in red only when cell membranes are disrupted. As shown in Figure 3, in the DAPI channel, both MRSA and *E. coli* exhibited blue fluorescence in the absence of compound P1. In the PI channel, neither strain showed red fluorescence before treatment, indicating the

Table 2. Activity and selectivity of polymyxin mimic peptides.

Cpd	MIC ($\mu\text{g}/\text{mL}$)				HC ₅₀ ($\mu\text{g}/\text{mL}$)	SI (HC ₅₀ /MIC _{MRSA})
	Gram Positive		Gram Negative			
	MRSA	MRSE	<i>E. coli</i>	<i>P. A.</i>		
P1	6.25	3.12	6.25	6.25	125	20
P2	12.5	>50	6.25	12.5	62.5	5
P3	25	>50	3.12	25	>250	>10
P4	12.5	>50	25	>50	>250	>20
Colist in	>50	>50	0.5	0.5	>250	>5




Figure 3. Fluorescence micrographs of MRSA and *E. coli* treated or not treated with 2 x MIC of compound **P1** for 2 h.

membranes of these bacteria were intact. However, after treatment with compound **P1** for 2 h at 2 x MIC, both MRSA and *E. coli* exhibited red fluorescence, suggesting that the membranes of both MRSA and *E. coli* were compromised.

To understand the bacteria membrane-disruptive kinetics, time kill assay of compound **P1** was also carried out. MRSA and *E. coli* was treated with different concentrations of compound **P1**: 2x MIC, 4x MIC and 8x MIC. In Figure 4, MRSA could be eliminated within 60 min at all three concentrations. Growth of *E. coli* was also effectively prevented at all three concentrations. The result indicate that compound **P1** could rapidly kill MRSA and arrest the growth of *E. coli* bacteria strains.

Inhibition of biofilm was also studied since biofilm has strong tolerance to antibiotics and can cause contamination by adhering to solid surface.²⁶ As shown in Figure 5., 10% of biofilm of *E. coli* bacteria was inhibited by compound **P1** at as low as 0.03 $\mu\text{g}/\text{mL}$ and 50% was inhibited at 3 $\mu\text{g}/\text{mL}$. At concentration of 6 $\mu\text{g}/\text{mL}$, more than 80% of bacteria was eradicated by compound **P1**. Biofilm data showed that **P1** could effectively




Figure 4. Time-kill plot of compound **P1** against MRSA (a) and *E. coli*. (b)




Figure 5. Biological activity of **P1** in the inhibition of a biofilm by *E. coli* (a). Drug resistance study for compound **P1** against *E. coli* (b).




Figure 6. *In vivo* efficacy of the compounds **P1** in the thigh-infection mouse model. (*: 0.02 < P value < 0.033)

inhibit the formation of bacteria biofilm which makes it a promising antibiotic agent.

Since compound **P1** was designed to be membrane active and disrupt bacterial membranes rather than acting on specific targets, we hypothesized that **P1** could also prevent the development of resistance in bacteria. Therefore, we carried out drug resistance studies for **P1** against *E. coli*. To do so, **P1** was incubated with *E. coli* at half of its MIC overnight, and the new MIC was measured subsequently. After 12 passages, the MICs of **P1** remained relatively stable (Figure 5), which strongly suggests that **P1** does not readily induce resistance in bacteria, thereby augmenting their therapeutic potential.

The development of membrane-active antibacterial peptides has been hindered by difficulties with systematic toxicity and tissue distribution, thus only a few compounds have been reported with *in vivo* activity and advanced into clinical trials. Polymyxins were investigated for their activity toward Gram-negative bacteria, however, their *in vivo* activity toward Gram-positive bacteria is rare. We envisioned that **P1** may possess *in vivo* activity against MRSA and thus could have better therapeutic potential than colistin toward Gram-positive bacterial strains. As such, we employed the thigh burden model, which is a widely used animal model for evaluating preclinical antimicrobial activity of compounds, to evaluate the *in vivo* anti-infective activity of compounds **P1**.²⁷ Thigh muscle of neutropenic mice was inoculated with MRSA, followed by intravenous (i.v.) injections of the compound **P1**. As shown in Figure 6, significant activity was observed at the dose of 5 mg/kg when administered twice with a 12 h interval between each injection. A 4-log₁₀ decrease in colony-forming unit (CFU) was observed. *In vivo* results suggested that compound **P1** provided significant antibiotic activity against infection with MRSA.

In summary, we have made a few polymyxin derivatives. Unlike colistin, these compounds possess potent and broad-spectrum antimicrobial activity against a panel of multidrug-resistant Gram-positive and Gram-negative bacteria. Our studies suggest that the lead compound could kill bacteria rapidly and the susceptibility of MRSA remained stable even after 12 passages. Furthermore, results of MRSA-infected thigh burden mouse model suggested great antibiotic therapeutic potential of the lead compound. Therefore, these compounds could be potential broad-spectrum antibiotic agents to combat drug resistance. Further studies on the optimization of activity and selectivity are currently underway.

The work was supported by NSF 1708500 and NIH 1R01GM112652.


- 26 S. Padhee, Y. Li and J. Cai, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 2565-2569.
 27 S. Choi, A. Isaacs, D. Clements, D. Liu, H. Kim, R. W. Scott, J. D. Winkler and W. F. DeGrado, *Proc. Natl. Acad. Sci. USA.*, 2009, **106**, 6968-6973.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 D. Landman, C. Georgescu, D. A. Martin and J. Quale, *Clin. Microbiol. Rev.*, 2008, **21**, 449-465.
- 2 J. Li, R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner and D. L. Paterson, *Lancet Infect. Dis.*, 2006, **6**, 589-601.
- 3 P. J. Bergen, C. B. Landersdorfer, J. Zhang, M. Zhao, H. J. Lee, R. L. Nation and J. Li, *Diagn. Microbiol. Infect. Dis.*, 2012, **74**, 213-223.
- 4 P. Leroy, D. Decolin, S. Nicolas, P. Archimbault and A. Nicolas, *J. Pharm. Biomed. Anal.*, 1989, **7**, 1837-1846.
- 5 S. J. Wallace, J. Li, R. L. Nation, R. J. Prankerd, T. Velkov and B. J. Boyd, *J. Phys. Chem. B*, 2010, **114**, 4836-4840.
- 6 P. J. Bergen, J. Li, C. R. Rayner and R. L. Nation, *Antimicrob. Agents Chemother.*, 2006, **50**, 1953-1958.
- 7 A. Poudyal, B. P. Howden, J. M. Bell, W. Gao, R. J. Owen, J. D. Turnidge, R. L. Nation and J. Li, *J. Antimicrob. Chemother.*, 2008, **62**, 1311-1318.
- 8 L. M. Lim, N. Ly, D. Anderson, J. C. Yang, L. Macander, A. Jarkowski, A. Forrest, J. B. Bulitta and B. T. Tsuji, *Pharmacother.*, 2010, **30**, 1279-1291.
- 9 A. P. Zavascki, L. Z. Goldani, J. Li and R. L. Nation, *J. Antimicrob. Chemother.*, 2007, **60**, 1206-1215.
- 10 H. Nikaido, *Microbiol. Mol. Biol. Rev.*, 2003, **67**, 593.
- 11 T. Velkov, K. D. Roberts, R. L. Nation, P. E. Thompson and J. Li, *Future Microbiol.*, 2013, **8**, 711-724.
- 12 T. Velkov, P. E. Thompson, R. L. Nation and J. Li, *J. Med. Chem.*, 2010, **53**, 1898-1916.
- 13 H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg and J. Bartlett, *Clinical infectious diseases : an official publication of the Clin. Infect. Dis.*, 2009, **48**, 1-12.
- 14 G. H. Talbot, J. Bradley, J. J. E. Edwards, D. Gilbert, M. Scheld and J. G. Bartlett, *Clin. Infect. Dis.*, 2006, **42**, 657-668.
- 15 E. E. Martin, J. F. David and P. R. Robert, *Ann. Pharmacother.*, 1999, **33**, 960-967.
- 16 J. Li and R. L. Nation, *Clin. Infect. Dis.*, 2006, **43**, 663-664.
- 17 J. Li, R. L. Nation, R. W. Milne, J. D. Turnidge and K. Coulthard, *Int. J. Antimicrob. Agents*, 2005, **25**, 11-25.
- 18 L. Fernández, C. Álvarez-Ortega, I. Wiegand, J. Olivares, D. Kocíncová, J. S. Lam, J. L. Martínez and R. E. W. Hancock, *Antimicrob. Agents Chemother.*, 2013, **57**, 110.
- 19 S. A. Loutet, L. E. Mussen, R. S. Flannagan and M. A. Valvano, *Environ. Microbiol. Rep.*, 2010, **3**, 278-285.
- 20 C. R. H. Raetz and C. Whitfield, *Annu. Rev. Biochem.*, 2002, **71**, 635-700.
- 21 Y. Niu, Y. Hu, X. Li, J. Chen and J. Cai, *New J. Chem.*, 2011, **35**, 542-545.
- 22 Y. Shi, P. Teng, P. Sang, F. She, L. Wei and J. Cai, *Acc. Chem. Res.*, 2016, **49**, 428-441.
- 23 S. Singh, A. Nimmagadda, M. Su, M. Wang, P. Teng and J. Cai, *Eur. J. Med. Chem.*, 2018, **155**, 398-405.
- 24 M. Su, D. Xia, P. Teng, A. Nimmagadda, C. Zhang, T. Odom, A. Cao, Y. Hu and J. Cai, *J. Med. Chem.*, 2017, **60**, 8456-8465.
- 25 P. Teng, A. Nimmagadda, M. Su, Y. Hong, N. Shen, C. Li, L.-Y. Tsai, J. Cao, Q. Li and J. Cai, *Chem. Commun.*, 2017, **53**, 11948-11951.



Compound	MIC ($\mu\text{g/mL}$)			
	Gram Positive		Gram Negative	
	MRSA	MRSE	<i>E. coli</i>	<i>P. A.</i>
P1	6.25	3.12	6.25	6.25

A few polymyxin derivatives with broad-spectrum antimicrobial activity were developed. Lead compound **P1** disrupted bacterial membranes rapidly without developing resistance.